Loading
Life sciences · Journal article
Journal of Liposome Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Melanoma is a treatment-resistant and highly aggressive form of skin cancer. The aberrant activation of the Wnt/β-catenin pathway is a key driver of proliferation, tumor progression, and metastasis in many cancers, including melanoma. The active involvement in tumor growth and immune evasion makes the Wnt/β lipoplexes-catenin pathway a critical therapeutic target. Recent advancements in gene delivery systems, such as liposomal nanoparticles (LNPs), have opened new possibilities for targeted cancer therapies by efficiently delivering genetic material, including microRNA (miRNA), to cancer cells with minimal off-target effects. Among potential gene-based therapies, miR-124 has emerged as a promising candidate for targeting the Wnt/β-catenin pathway. However, a major challenge in miRNA-based therapeutics is the efficient delivery of miRNA to tumor cells. By using cationic liposomes to form lipoplexes with miR-124 plasmids, we aim to evaluate the efficiency of lipoplex-mediated delivery and transfection in both in vitro and in vivo melanoma models and observe their effects on WNT/β-catenin signaling and tumor growth. The application of lipoplexes in gene-based therapies represents a promising approach to improve treatment outcomes for melanoma patients.